Activity Title: Virtual Symposium: Patient-focused LDL-C Management and Risk Reduction in Clinical Practice: The Utility of PCSK9 Inhibitors
Activity Format: Virtual Symposium
Program Description:
During this comprehensive learning experience, expert faculty will examine current lipid guidelines, the unmet need and residual risk of poorly controlled LDL-C, and exciting genetic insights that have expanded treatment targets. Participants will leave with the latest information on novel LDL lowering therapies, including PCSK9 inhibitors. Clinical case examples will provide tactics for treatment intensification and how best to integrate new therapies into management plans for high-risk patients.
Estimated Time to Complete: 1.5 hours
Release Date: December 19, 2016
Expiration Date: December 19, 2017
Credit Type(s) Available: ACCME, CDR, ANCC
Maximum Credits: 1.5 AMA PRA Category 1 Credit(s)™
Provided By: This activity is jointly provided by Medical Education Resources, Inc (MER) and Tarsus Cardio Inc. dba Cardiometabolic Health Congress.
Commercial Supporter:
Supported by an educational grant from Sanofi-aventis US and Regeneron Pharmaceuticals.
Purpose Statement:
To improve patient outcomes through early identification and intervention strategies for patients with, or at risk of developing, diabetes and cardiovascular disease.
Intended Audience:
This activity is designed for advanced-level clinicians responsible for the prevention, diagnosis, and management of cardiometabolic risk.
Educational Objectives:
Upon completion of this activity, participants should be able to:
- Identify patient populations at high residual risk of CVD, despite statin therapy, particularly those with FH, ASCVD, or statin intolerance
- Assess the genetic basis and mechanistic rationale for lowering LDL-C through novel pathways, and the importance of LDL receptor recycling in cholesterol homeostasis.
- Review the latest clinical trial data and physiologic rationale for the practicalities of administration and patient selection.
Faculty Information:
Christie M. Ballantyne, MD
- Professor of Medicine
- Chief, Section of Cardiovascular Research
- Chief, Section of Cardiology
- Department of Medicine, Baylor College of Medicine
- Director, Center for Cardiovascular Disease Prevention
- Baylor College of Medicine
- Methodist DeBakey Heart Center
- Houston, TX
Grants/Research Support: Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Novartis, Pfizer, Otsuka, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, Takeda, NIH, AHA, ADA
Consulting Fees: Abbott Diagnostic, Amarin, Amgen, AstraZeneca, Eli Lilly, Esperion, Genzyme, ISIS, Matinas BioPharma Inc, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi-Synthelabo
Henry N. Ginsberg, MD
- Irving Professor of Medicine
- Director, Irving Institute for Clinical & Translational Research
- Columbia University
- New York, NY
Grants/Research Support: Amgen, Sanofi Regeneron, Merck
Consulting Fees: Kowa, Amgen, Sanofi Regeneron, Merck, Janssen Pharmaceuticals, Inc., AstraZeneca, Novartis, Pfizer, Ionis Pharmaceuticals, Inc.
James A. Underberg, MD
- Lipidology & Cardiovascular Disease Prevention
- Clinical Assistant Professor of Medicine
- NYU Medical School & NYU Center for CV Prevention
- Director, Bellevue Hospital Lipid Clinic
- President-Elect National Lipid Association
- New York, NY
Grants/Research Support: Pfizer, Aegerion, Gemphire, FH Foundation
Consulting Fees: Akcea, Amgen, Lilly, Recombine, Amarin Speakers’ Bureau: Regeneron, Alexion, Genzyme, Amgen, Sanofi, Merck
Disclosure of Conflicts of Interest:
It is the policy of MER to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Provider Disclosures:
The following content managers reported no financial relationships with commercial interests whose products or services may be mentioned in this CME/CE activity:
MER: Julie Johnson, PharmD, Veronda Smith, FNP
CMHC: Erin Franceschini, MS, Mary Mihalovic, Karin McAdams
Accreditation
Physician Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources and Tarsus Cardio Inc. dba Cardiometabolic Health Congress. Medical Education Resources is accredited by the ACCME to provide continuing medical education for physicians.
Medical Education Resources designates each enduring material for a maximum of 1.5 AMA PRA Category 1 credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nursing Credit
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Each CE activity provides 1.5 contact hour of continuing nursing education.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.5 contact hour.
Dietician Credit
Medical Education Resources (Provider Number ME110) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of each program/material.
(CDR Activity Number: 130748)
Disclaimer:
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of MER, CMHC and/or the various industry supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MER, CMHC, and/or the various industry supporters. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
Instructions for CME/CE Credit:
Participants are expected to answer all delivered questions before attempting to complete the post-test and evaluation for that activity. Successful completion will lead to the issuance of a certificate for 1.5 AMA PRA Category 1 Credit(s)™.
To receive credit, the course must be completed on or before December 19, 2017.
There are no fees for participating in and receiving CME credit for this activity. In order to claim CME credit for this activity registration is required prior to viewing the activity.
During the period December 19, 2016 through December 19, 2017, participants must follow these steps in order to receive CME/CE credit:
- Sign In or Register at https://www.cardiometabolichealth.org/my-account.html
- Read and accept the Terms & Conditions including the learning objectives and faculty disclosures.
- Complete the pre-test by recording the best answer to each question in the answer key. There is no scoring of the pre-test questions section.
- Review the educational activity.
- Complete the post-test by recording the best answer to each question in the answer key. Successful completion of the post-test is required to earn CME/CE credit. Successful completion is defined as a cumulative score of at least 70%.
- Complete the online evaluation form.
- After successfully completing the post-test and online evaluation form, your CME/CE certificate will be generated and will be available immediately for print.
Hardware and Software Requirements:
This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.
Policy on Privacy and Confidentiality:
(MER) protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. MER and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting to the appropriate accrediting agency. To view the MER privacy policy, please click here. MER and CMHC maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your non-public personal information.
MER can be contacted by e-mail at data@mer.org or by telephone at 303-798-9682.
